NASDAQ:ANAB

AnaptysBio News Headlines

$26.25
+0.40 (+1.55 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.03
$26.50
50-Day Range
$22.98
$27.01
52-Week Range
$13.92
$35.85
Volume147,504 shs
Average Volume338,506 shs
Market Capitalization$720.12 million
P/E RatioN/A
Dividend YieldN/A
Beta0.06

Media Mentions By Week

AnaptysBio Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ANAB
News Sentiment

0.30

0.30

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ANAB Articles
This Week

2

2

ANAB Articles
Average Week

Get AnaptysBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

AnaptysBio (NASDAQ ANAB) News Headlines Today

SourceHeadline
Sinusitis (Ear Nose Throat Disorders) Drugs Pipeline Landscape Report 2021 - ResearchAndMarkets.com - Business WireSinusitis (Ear Nose Throat Disorders) Drugs Pipeline Landscape Report 2021 - ResearchAndMarkets.com - Business Wire
businesswire.com - September 13 at 3:23 PM
AnaptysBio to Participate in the HC Wainwright 23rd Annual Global Investment Conference - GlobeNewswireAnaptysBio to Participate in the HC Wainwright 23rd Annual Global Investment Conference - GlobeNewswire
globenewswire.com - September 10 at 6:34 PM
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceAnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 4:24 PM
AnaptysBio, Inc. (NASDAQ:ANAB) Expected to Announce Quarterly Sales of $8.35 MillionAnaptysBio, Inc. (NASDAQ:ANAB) Expected to Announce Quarterly Sales of $8.35 Million
americanbankingnews.com - September 4 at 2:26 AM
Zacks: Analysts Anticipate AnaptysBio, Inc. (NASDAQ:ANAB) Will Announce Earnings of -$0.78 Per ShareZacks: Analysts Anticipate AnaptysBio, Inc. (NASDAQ:ANAB) Will Announce Earnings of -$0.78 Per Share
americanbankingnews.com - September 2 at 3:16 PM
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Hold" by BrokeragesAnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - August 25 at 11:28 AM
Research Analysts Offer Predictions for AnaptysBio, Inc.s Q1 2022 Earnings (NASDAQ:ANAB)Research Analysts Offer Predictions for AnaptysBio, Inc.'s Q1 2022 Earnings (NASDAQ:ANAB)
americanbankingnews.com - August 23 at 1:30 AM
Health Care Sector Update for 08/18/2021: NRXP,AZRX,HOWL,ANAB - NasdaqHealth Care Sector Update for 08/18/2021: NRXP,AZRX,HOWL,ANAB - Nasdaq
nasdaq.com - August 19 at 1:46 AM
Health Care Sector Update for 08/18/2021: AZRX,HOWL,ANAB - NasdaqHealth Care Sector Update for 08/18/2021: AZRX,HOWL,ANAB - Nasdaq
nasdaq.com - August 18 at 3:42 PM
AnaptysBioFDA Grants Accelerated Approval Of GSKs JEMPERLI, Which Was Generated By AnaptysBio; Co. Has Earned $20M Milestone Payment As A Result - BenzingaAnaptysBioFDA Grants Accelerated Approval Of GSK's JEMPERLI, Which Was Generated By AnaptysBio; Co. Has Earned $20M Milestone Payment As A Result - Benzinga
benzinga.com - August 18 at 3:42 PM
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication - Yahoo FinanceAnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication - Yahoo Finance
finance.yahoo.com - August 18 at 3:42 PM
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) - GlobeNewswireFDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) - GlobeNewswire
globenewswire.com - August 17 at 6:12 PM
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid TumorsFDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
finance.yahoo.com - August 17 at 6:11 PM
Global Netherton Syndrome Market 2021-2030 Featuring Major - GlobeNewswireGlobal Netherton Syndrome Market 2021-2030 Featuring Major - GlobeNewswire
globenewswire.com - August 14 at 8:57 AM
Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio - Yahoo FinanceGlobal Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio - Yahoo Finance
finance.yahoo.com - August 12 at 6:45 AM
Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies - GlobeNewswirePeanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies - GlobeNewswire
globenewswire.com - August 9 at 11:23 PM
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates - Yahoo FinanceAnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates - Yahoo Finance
finance.yahoo.com - August 9 at 11:23 PM
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 9 at 11:23 PM
AnaptysBio Announces Second Quarter 2021 Financial Results - GlobeNewswireAnaptysBio Announces Second Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - August 9 at 6:23 PM
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline UpdatesAnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
finance.yahoo.com - August 9 at 6:23 PM
Were Interested To See How AnaptysBio (NASDAQ:ANAB) Uses Its Cash Hoard To GrowWe're Interested To See How AnaptysBio (NASDAQ:ANAB) Uses Its Cash Hoard To Grow
finance.yahoo.com - August 7 at 1:32 PM
Novavax Inc. stock rises Thursday, outperforms market - MarketWatchNovavax Inc. stock rises Thursday, outperforms market - MarketWatch
marketwatch.com - August 7 at 8:32 AM
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors - Yahoo FinancePardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors - Yahoo Finance
finance.yahoo.com - August 5 at 7:36 PM
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early - Yahoo FinanceHedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early - Yahoo Finance
finance.yahoo.com - July 26 at 10:01 PM
Hedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too EarlyHedge Funds Cashed Out Of AnaptysBio, Inc. (ANAB) Too Early
finance.yahoo.com - July 26 at 10:01 PM
AnaptysBio gains after report the company received a takeover offer - Seeking AlphaAnaptysBio gains after report the company received a takeover offer - Seeking Alpha
seekingalpha.com - July 20 at 1:04 PM
Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Re - BenzingaHidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Re - Benzinga
benzinga.com - July 14 at 9:52 PM
Global Peanut Allergy Disease Clinical Trials Review - H1, 2021 - ResearchAndMarkets.com - Business WireGlobal Peanut Allergy Disease Clinical Trials Review - H1, 2021 - ResearchAndMarkets.com - Business Wire
businesswire.com - July 14 at 4:51 PM
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires - Markets InsiderShoreline Biosciences Strengthens Senior Management Team With Three Key Hires - Markets Insider
markets.businessinsider.com - July 13 at 3:18 PM
ANAB Jun 2021 25.000 putANAB Jun 2021 25.000 put
ca.finance.yahoo.com - June 13 at 2:02 PM
Novavax Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatchNovavax Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
marketwatch.com - June 11 at 5:58 PM
Vitiligo Pipeline - Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight - Yahoo FinanceVitiligo Pipeline - Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight - Yahoo Finance
finance.yahoo.com - June 3 at 10:59 PM
Novavax Inc. stock falls Friday, underperforms market - MarketWatchNovavax Inc. stock falls Friday, underperforms market - MarketWatch
marketwatch.com - May 28 at 6:56 PM
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - GlobeNewswireAnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference - GlobeNewswire
globenewswire.com - May 27 at 7:30 PM
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare ConferenceAnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 7:30 PM
Forecast: Analysts Think AnaptysBio, Inc.s (NASDAQ:ANAB) Business Prospects Have Improved Drastically - Yahoo FinanceForecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically - Yahoo Finance
finance.yahoo.com - May 11 at 2:32 AM
Analyst Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - NasdaqAnalyst Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Nasdaq
nasdaq.com - May 9 at 9:41 AM
Forecast: Analysts Think AnaptysBio, Inc.s (NASDAQ:ANAB) Business Prospects Have Improved DrasticallyForecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically
finance.yahoo.com - May 9 at 9:41 AM
AnaptysBio EPS beats by $0.03, beats on revenue - Seeking AlphaAnaptysBio EPS beats by $0.03, beats on revenue - Seeking Alpha
seekingalpha.com - May 5 at 12:40 AM
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates - NasdaqAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
nasdaq.com - May 4 at 7:39 PM
AnaptysBio Announces First Quarter 2021 Financial Results - GlobeNewswireAnaptysBio Announces First Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - May 4 at 7:39 PM
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline UpdatesAnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
finance.yahoo.com - May 4 at 7:39 PM
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue EstimatesAnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 4 at 7:39 PM
Last Weeks Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More - BenzingaLast Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More - Benzinga
benzinga.com - May 2 at 9:36 AM
AnaptysBio - BenzingaAnaptysBio - Benzinga
benzinga.com - May 2 at 9:36 AM
Novavax Inc. stock falls Friday, still outperforms market - MarketWatchNovavax Inc. stock falls Friday, still outperforms market - MarketWatch
marketwatch.com - April 30 at 7:53 PM
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline - Yahoo FinanceEarnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline - Yahoo Finance
finance.yahoo.com - April 28 at 2:05 PM
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to DeclineEarnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline
finance.yahoo.com - April 28 at 2:05 PM
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial CancerFDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
markets.businessinsider.com - April 24 at 9:06 AM
Novavax Inc. stock rises Friday, still underperforms market - MarketWatchNovavax Inc. stock rises Friday, still underperforms market - MarketWatch
marketwatch.com - April 23 at 6:08 PM
Get AnaptysBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.